TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06784765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Preventive pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin (10 mg/m2) and doxorubicin (2.1 mg/m2) + perioperative chemotherapy (FLOT regimen) +gastrectomy with D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Retrospective cohort receiving standard perioperative chemotherapy (FLOT regimen) + gastrectomy with D2 lymphadenectomy
Study: NCT06785857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Supportive Care Program
Description: On the basis of monthly home visits in the control group, a weekly mHealth supportive care intervention program was added through the medium of Xiamen iHealth, with one supportive care item every two weeks for 12 weeks, for a total of 12 online interventions, as well as the provision of online consulting and booking services for caregivers at any time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offline supportive care
Description: This was done routinely in accordance with the requirements of public health services for chronic diseases in the community elderly. In addition, health education on diabetes mellitus and dementia was provided to the caregivers during their monthly home visits.~① the content of diabetes health education: the researcher gave the caregivers education and training on the care of diabetes patients: the main points of care in diet, sleep, exercise, etc.~② The content of dementia health education: the researcher gave the caregivers education and training related to the care of dementia patients: instructing the caregivers in the basic life care skills of patients' diet, sleep, exercise, etc.
Study: NCT06784063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity Extended Vision IOL
Description: Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
Study: NCT06783686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV701
Description: eye drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine 1.25% Eye drop
Description: eye drop
Study: NCT06788119

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy with in vivo exposure
Description: CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure.In this condition participants will receive CBT treatment and be exposed to in vivo situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT
Description: CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure. In this condition participants will receive CBT treatment and be exposed to in vivo situations with the support of SYMPTOMS-JIT.
Study: NCT06786819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERACS with Digital Platform
Description: The assistance provided to patients in the intervention group will be sequential and prospective. The project will utilize an app based on protocols that prepare patients for rapid recovery (ERAS), starting before surgery and extending up to 30 days post-discharge. This includes pre-operative evaluations (dental, psychological, nutritional, and others), scheduling and confirming hospital admission, and following specific protocols during surgery and intensive care. The app aims to enhance communication and teamwork, improving patient-centered care. It will feature modules for patient and family education, team communication, and activity management through a dashboard. Additionally, it will facilitate interaction with patients through messages and surveys, monitor multidisciplinary team communication, and collect patient-reported outcomes 30 days after the surgical procedure.
Study: NCT06784024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Topical lidocaine (SPRAY SOLUTION 10 g) 10% will be applied to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml/spray).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo (0.9% saline) will be applied topically to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml / spray).
Study: NCT06783816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor gene modified T cells
Description: The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
Study: NCT06782906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ≥10,000 daily steps (≥5 days/week) and stopping evening snacking
Description: Participants in the intervention arm will be asked to perform ≥10,000 daily steps (≥5 days/week) and omit evening snacking after 8:00 p.m.
Study: NCT06786260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional Diet
Description: Low salt, limited caffeine, high potassium, low phosphate, and limited protein and carbohydrate intake along with adequate water intake diet
Study: NCT06785948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active-tDCS
Description: 2mA stimulation (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: No intensity applied (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).
Study: NCT06786130

Intervention type: OTHER
Intervention: observational study
Description: This is an observational study in which participants complete PRO questionnaires via a web platform. No medical intervention or medication is involved.
Study: NCT06787430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicorandil
Description: In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
Study: NCT06783296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal denervation performed using the Netrod® multi-electrode renal denervation system, which is approved for interventional treatment of hypertension. This procedure involves catheter-based radiofrequency ablation of the renal nerves to reduce sympathetic activity and lower blood pressure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal Angiography
Description: A sham procedure involving renal angiography without the application of radiofrequency energy. This control intervention is used to maintain blinding.
Study: NCT06782724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin therapy
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Study: NCT06785519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
Description: Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion
Study: NCT06786234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP938
Description: At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
Study: NCT06785818

Intervention type: OTHER
Intervention: Tisagenlecleucel
Description: This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.
Study: NCT06782841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMA-TULIP Laryngeal Mask
Description: After the anesthesia induction, use the GMA-TULIP laryngeal mask as the airway ventilation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel Laryngeal Mask
Description: After the anesthesia induction, use the i-gel laryngeal mask as an airway ventilation device.
Study: NCT06321120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: variability-based lenvatinib regimen
Description: Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
Study: NCT05600153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant exchange operation
Description: To perform implant exchange via axillary incision.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant exchange operation
Description: To perform implant exchange via axillary incision.
Study: NCT06782841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BlockBuster Laryngeal Mask
Description: After the anesthesia induction is over, use the BlockBuster laryngeal mask as the airway ventilation device.
Study: NCT06786442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFFACLAR DUO+M CREAM
Description: twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFFACLAR DUO+M CREAM
Description: twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFFACLAR DUO+M CREAM
Description: twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)
Study: NCT06784570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosemindan
Description: In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adrenaline,noreadrenaline,dopamine and doputamine
Description: adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
Study: NCT06785571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride injection
Description: a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride injection
Description: a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride injection
Description: a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride injection
Description: A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride injection
Description: A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
Study: NCT06783907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-invasive blood glucose monitoring
Description: Non-invasive wearable glucose monitoring device for capturing participants' blood glucose.~The intervention will include:~1. Training for self-management of diabetes and phone consultation.~2. Follow-up through phone calls or WhatsApp for hypoglycaemic or hyperglycaemic events.~3. Personalized care guided by sensor data.~The Investigator will monitor the health data from the device regularly. A mobile app will track and record compliance with blood glucose monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional blood glucose monitoring
Description: Traditional blood glucose monitoring~Participants will engage in traditional self-monitoring of blood glucose at home over the course of 8 weeks. They are recommended to check their blood glucose levels one to two times per week and record all results. This will allow for the collection of data using traditional monitoring methods.
Study: NCT06784193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-3136
Description: OP-3136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-3136
Description: OP-3136
Study: NCT05771454

Intervention type: PROCEDURE
Intervention: Histopathological confirmation
Description: After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
Study: NCT03843320

Intervention type: DEVICE
Intervention: SAPIEN 3
Description: Transcatheter aortic valve replacement

Intervention type: DEVICE
Intervention: SAPIEN XT
Description: Transcatheter aortic valve replacement

Intervention type: DEVICE
Intervention: INSPIRIS RESILIA
Description: Surgical aortic valve replacement

Intervention type: DEVICE
Intervention: EDWARDS INTUITY
Description: Surgical aortic valve replacement

Intervention type: DEVICE
Intervention: Carpentier-Edwards PERIMOUNT Magna-Ease
Description: Surgical aortic valve replacement
Study: NCT06477380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCEPT intervention
Description: * Training package (1 day)~* A toolkit/manual for clinicians to guide them through the disclosure process~* Trauma-informed changes to the physical environment~* Monthly trauma-focussed reflective group for care co-ordinators
Study: NCT04953806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-CBT
Description: Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
Study: NCT04499833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transplant
Description: liver transplant
Study: NCT06472687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+ warm-up exercise training
Description: FIFA 11+ warm-up training program was applied to the experimentel group. control group (CG) did their usual warm-up program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm-up exercise training
Description: exercise training
Study: NCT06784193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-3136
Description: OP-3136
Study: NCT06786871

Intervention type: PROCEDURE
Intervention: IVF treatment
Description: Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
Study: NCT06782711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cranioplasty
Description: In this pivotal study of a medical device, patients with bone loss undergo a computed tomography scan, which is used to create a three-dimensional model of the lesion. After validation, the model is printed using PEEK material, and subsequently, the skull is repaired through cranial reconstruction (cranioplasty).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized skull implants made of polyetheretheretherketone (PEEK) using 3D printing
Description: customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty
Study: NCT06785428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will vary between 0.2 to 2.8 g/kg/d.
Study: NCT06787547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVL(Sonico-CX)
Description: SONICO-CX® balloon matched 1:1 to the reference vessel diameter, was advanced to the target lesion to pretreat
Study: NCT06786247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActivaTeen
Description: The ActivaTeen app is built on HIPAA-compliant instance of a popular messaging software. Participants in the treatment group can access the app at any time via desktop or mobile, where they can find features designed to enhance their receipt of BA therapy.~These features include: weekly BA skills and homework completion support, in-app messaging with their BA therapist, mood and activity tracking and data visualizations, chatbot check-ins on progress and guided problem-solving around barriers, and moderated peer support using the ActivaTeen app. The app will have a moderator, who is part of the study team, to manage peer-to-peer interactions within ActivaTeen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation therapy involves individual weekly sessions with a trained therapist for 12 weeks. The sessions are completed either in-person or via telehealth. The treatment focuses on behavioral manifestations of depression such as isolating, and how these behaviors are interconnected with low mood and depressive emotions. BA helps patients find ways to engage in behaviors that are meaningful to them based on their values, priorities, and goals, with the aim of creating positive loops between doing meaningful activities and improved mood. The therapist provides structure and problem-solving for activating these behaviors and keeping track of changes over time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral activation therapy involves individual weekly sessions with a trained therapist for 12 weeks. The sessions are completed either in-person or via telehealth. The treatment focuses on behavioral manifestations of depression such as isolating, and how these behaviors are interconnected with low mood and depressive emotions. BA helps patients find ways to engage in behaviors that are meaningful to them based on their values, priorities, and goals, with the aim of creating positive loops between doing meaningful activities and improved mood. The therapist provides structure and problem-solving for activating these behaviors and keeping track of changes over time.
Study: NCT06783933

Intervention type: DIAGNOSTIC_TEST
Intervention: surgical or interventional validation
Description: surgical or interventional validation

Intervention type: DIAGNOSTIC_TEST
Intervention: surgical or interventional validation
Description: surgical or interventional validation
Study: NCT06783751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Vertical Sleeve Gastrectomy (mVSG)
Description: The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Vertical Sleeve Gastrectomy (cVSG)
Description: Vertical Sleeve Gastrectomy as standard procedure
Study: NCT04576104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies